Exopharm Limited (EX1)
20mins delayed
Movement
1 Year Return
Exopharm Limited Chart
| Share price | |
| Last | |
| Change | |
| Volume | |
| Turnover | |
| Market Cap | $24.48 million |
| Today's Movement | |
| Prev. Close | |
| Open | |
| Day Range | - |
| VWAP | |
| Historical Stats | |
| 52w Range | - |
| 4w Avg Volume | |
| 4w Avg Turnover | |
| (delayed) | |
EX1 Statistics
17 September
1,349 / 2,298
ASX Size Rank
1yr Return
vs Sector (1yr)
-32.51%
vs ASX 200 (1yr)
-29.41%
$24.48 million
Market Cap
Share Issue
59.71 million
All Ords (%)
N/A
Short Sold
0%
Current Fundamentals
17 September
N/A
PE Ratio
EPS ($)
-0.04
Earnings Yield
-9.83%
NTA ($)
0.09
N/A
Dividend Yield
DPS ($)
-
Gross Div. Yield
-
Gross DPS ($)
-
Company Overview
Exopharm Limited (EX1) operates in the healthcare sector, specifically in the regenerative medicine industry. As its primary focus, Exopharm aims to be a leader in the field of clinical human therapeutics using exosomes as regenerative medicine products. Exopharm seeking to develop and commercialise exosomes as therapeutic agents – initially a product called Plexaris and later as a product called Exomeres. These products are exosomes that are derived from human platelets in relation to Plexaris, and adult stem cells in relation to Exomeres, and purified using the LEAP Technology and referred to as biologic products. Exopharm's key asset is the LEAP Technology (which includes the Patent Applications) and associated know-how.
Upcoming Calendar
Dividend History
| Ex-Date | Amount | Franking | Type | Payable |
|---|---|---|---|---|
| No dividends paid in the last 5 years | ||||
See Upcoming Dividends for all ASX companies.
Announcements
| Date | Heading | Pages | File Size | Time |
|---|---|---|---|---|
Broker Consensus
The buy, hold and sell recommendations from Australian stockbroking firms are combined to form a "broker consensus". See the Consensus Data posts for more information.
EX1 is not covered by a major broker.
Directors & Management
| Name | Title | Since | Bio |
|---|---|---|---|
| Mr David Rodney Parker | Company Secretary, Non-Executive Director | Jun 2018 |
|
| Dr Ian Edward Dixon | Company Founder, Technology Co-Founder, Managing Director | May 2013 |
|
| Mr Jason Mark Watson | Non-Executive Chairman, Non-Executive Director | Aug 2018 |
|
Director Transactions
EX1 directors must report any change in shareholding to the ASX within 5 business days.
See Director Transactions for all ASX companies.
| Date | Director | Type | Amount | Price | Value | Notes |
|---|---|---|---|---|---|---|
| 19/08/19 | David Parker | Buy | +20,000 | $0.370 | $7,400 | Participation in share purchase plan. |
| 19/08/19 | Ian Dixon | Buy | +40,000 | $0.370 | $14,800 | Participation in share purchase plan. |
| 19/08/19 | Jason Watson | Buy | +40,000 | $0.370 | $14,800 | Participation in share purchase plan. |
Shareholder Distribution
Shareholder Distribution data is unavailable.
Top 20 Shareholders
| Name | Shares | Capital |
|---|---|---|
| Altnia Holdings Pty Ltd |
27,935,294 | 34.70% |
| Mr Michael Francis Mcmahon & Mrs Susan Lesley Mcmahon |
2,385,000 | 2.96% |
| Oldview Enterprises Pty Ltd |
1,345,834 | 1.67% |
| Anthony John Locantro | 1,330,000 | 1.65% |
| Citicorp Nominees Pty Limited | 1,250,000 | 1.55% |
| Phytose Corporation Pty Ltd |
1,176,471 | 1.46% |
| Pabasa Pty Ltd |
1,000,000 | 1.24% |
| Carda Pty Ltd |
965,000 | 1.20% |
| Mrs Anna Felicia Belton | 920,833 | 1.14% |
| Basapa Pty Ltd |
750,000 | 0.93% |
| Drp 2006 Super Pty Ltd |
740,000 | 0.92% |
| Sunshine Group Investments Pty Ltd |
700,000 | 0.87% |
| Lonhro (WA) Pty Ltd |
686,667 | 0.85% |
| Saintly Company Pty Ltd |
680,000 | 0.84% |
| ACNS Capital Markets Pty Ltd | 667,800 | 0.83% |
| Mr Andrew Stewart Coles & Ms Alexandra Constancemanook |
625,000 | 0.78% |
| Gregor Lichtfuss | 588,235 | 0.73% |
| Aukera Capital Pty Ltd | 500,000 | 0.62% |
| Kohen Enterprises Pty Ltd | 500,000 | 0.62% |
| Labonne Enterprises Pty Ltd |
500,000 | 0.62% |
| Mr Craig Ian Brown & Mrs Jenny Lee Brown |
500,000 | 0.62% |
| Jecss Pty Ltd |
500,000 | 0.62% |
| Brisque Pty Ltd |
500,000 | 0.62% |
| Ringsford Pty Ltd |
475,000 | 0.59% |
| GAIL Garrity Pty Ltd |
408,666 | 0.51% |
| All other shareholders | 40.86 % | |
The Top 20 Shareholders of EX1 hold 59.14% of shares on issue.
EX1 Share Price History
| Date | Close | Change | % Change | Open | High | Low | Volume | Turnover |
|---|---|---|---|---|---|---|---|---|
EX1 Historical Data
Download up to 20 years of share price history.
| Year | Closing Price (30 June) | Last Trade |
|---|
Offical data as published by ASX. See more Data Downloads.
Company Details
Principal Activity: Biopharmaceutical research with a primary focus on developing and commercialising exosomes as therapeutic agents.
Incorporated: --
Level 17, 31 Queen St
Melbourne VIC 3000
All data on this page is supplied by the ASX, Morningstar and Market Index. Read the disclaimer.